I'd rather see one of the compounds they are testing move to human trials far more than I want to see them announce some other new patent for some other disease that they are going to start testing.
They don't have any money or time to be wasting on starting new studies. They need to start progressing the ones they've already begun. Otherwise it starts to come off as pumping. It's like when you start 18 different projects, but don't complete any of them. That isn't worth much. I think the retail market agrees as these PRs have done little for the share price.
I also wouldn't get too overzealous about the Aegis underwriting deal, yet. In November 2018 they made a deal with GHS Investment LLC for $10 million in funding along with the last reverse split. It took effect in February 2019, a 20 to 1 r/s that took the PPS from around a penny to around 30 cents. 9 months later the price had steadily dropped back down to pennies. After a year or so it was sub penny. They need to update on what they have already been working on, not throw out new potential treatments for other illnesses. Otherwise this pps isn't going anywhere.
We need COVID mice results or Cancer mice results. Anything else is fluff right now. It's a crucial time now that we have a deadline for the end of October on the whole Aegis deal/reverse split/NASDAQ uplist attempt. The price needs to jump to new 52 week high if this is going to work out, and the only thing that will do that right now is progress on the COVID or cancer studies, more likely the COVID one as it has been in mice testing for 7+ months.
All just IMO,
GLTA
